Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, Tregs and FOXP3+ cancer cells in locally advanced pancreatic cancer.

Yves Boucher Jessica M Posada Sonu Subudhi Ashwin Srinivasan Kumar Spencer R Rosario Liqun Gu Heena Kumra Mari A Mino-Kenudson Nilesh P Talele Dan G Duda Dai Fukumura Jennifer Y Wo Jeffrey W Clark David P Ryan Carlos F Fernandez-Del Castillo Theodore S Hong Mikaël J Pittet Rakesh K Jain

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Adding losartan to FFX+CRT reduced pro-invasion and immunosuppression related genes which were associated with improved OS in patients with LAPC. Lesions from responders in the LOS+FFX+CRT-treated group had reduced Tregs, decreased C-FOXP3 and increased CD8+ T cells. These findings suggest that losartan may potentiate the benefit of FFX+CRT by reducing immunosuppression.

Keyphrases

locally advanced
rectal cancer
cardiac resynchronization therapy
regulatory t cells
angiotensin ii
neoadjuvant chemotherapy
squamous cell carcinoma
radiation therapy
phase ii study
left ventricular
heart failure
genome wide
gene expression
dna methylation
newly diagnosed
bioinformatics analysis
immune response